Consequences of chemotherapy on resection of colorectal liver metastases;Conséquences de la chimiothérapie sur la résection des métastases hépatiques d'origine colorectale

Journal de Chirurgie Viscerale

Volumn 147, Issue 4, 2010, Pages 255-264

  Pessaux, P ^a   Chenard, M P ^a   Bachellier, P ^a   Jaeck, D ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Chemotherapy; Resection of colorectal liver metastases

Indexed keywords

EID: 79960223733     PISSN: 1878786X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchirv.2010.06.005     Document Type: Short Survey

References (77)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66. (Pubitemid 46148091)
2. Remontet L, Estève J, Bouvier AM, et al. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique 2003;51:3-30. (Pubitemid 36813955)
3. Fong Y, Kemeny N, Paty P, et al. Treatment of colorectal cancer: hepatic metastasis. Semin Surg Oncol 1996;12:219-52. (Pubitemid 26255863)
4. Steele GJ, Ravikumar TS. Resection of hepatic metastases from colorectal carcinoma: biologic perspectives. Ann Surg 1989;210:127-38. (Pubitemid 19188702)
5. Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006;94:982-99.
6. Jaeck D, Bachellier P, Guiguet M, et al. Long-term survival following resection of colorectal hepatic metastases: Association Française de Chirurgie. Br J Surg 1997;84:977-80. (Pubitemid 27310867)
7. Nordlinger B, Sorbye H, Collette L, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007-16. (Pubitemid 351392040)
8. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluoro-uracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005;23:9441-2.
9. Tanaka K, Adam R, Shimada H, et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003;90:963-9. (Pubitemid 37026325)
10. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005;23:2038-48. (Pubitemid 46211384)
11. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-22. (Pubitemid 26337559)
12. Miyanari N, Mori T, Takahashi K, et al. Evaluation of aggressively treated patients with unresectable multiple liver metastases from colorectal cancer. Dis Colon Rectum 2002;45:1503-9. (Pubitemid 35345877)
13. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644-57.
14. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663-9. (Pubitemid 29342371)
15. Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liveronly metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005;23:9243-9.
16. de la Camara J, Rodriguez J, Rotellar F, et al. Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer. Proc Am Soc Clin Oncol 2004;23:268.
17. Ychou M, Viret F, Kramar A, et al. Tritherapy with fluorouracil/ leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with nonresectable liver metastases. Cancer Chemother Pharmacol 2008;62:195-201. (Pubitemid 351692073)
18. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004;15:933-9. (Pubitemid 39004350)
19. Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009;249:420-5.
20. Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005;16:1311-9. (Pubitemid 41158476)
21. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (Fol-Foxiri) compared with infusional fluorouracil, leucoverin, and irinotecan (Folfiri) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670-6. (Pubitemid 46797946)
22. Hurwitz H, Fehrenbacher L, NovotnyW, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42. (Pubitemid 38702844)
23. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45. (Pubitemid 38944402)
24. Adam R, Aloia T, Levi F, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007;25:4593-602. (Pubitemid 350035318)
25. Van Cutsem E, Köhne CH, Hiltre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
26. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer/the BEAT study. Ann Oncol 2009;30, mdp233v1-mdp233.
27. Allen PJ, Kemeny N, Jarnagin W, et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003;7:109-15.
28. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240:1052-60.
29. Kornprat P, Jarnagin WR, Gonen M, et al. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol 2007;14:1151-60.
30. Jaffe CC. Measures of responses: RECIST, WHO, and new alternatives. J Clin Oncol 2006;24:3245-51. (Pubitemid 46622065)
31. Small RM, Lubezky N, Shmueli E, et al. Response to chemotherapy predicts survival following resection of hepatic colorectal metastases in patients treated with neoadjuvant therapy. J Surg Oncol 2009;99:93-8.
32. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol 2007;18:299-304. (Pubitemid 46323097)
33. Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 2008;26:1635-41.
34. Blazer DG, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end-point after resection of hepatic colorectal metastases. J Clin Oncol 2008;25:5344-51.
35. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007;110:2761-7. (Pubitemid 350250347)
36. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstructive syndrome (veno-occlusive disease). Semin Liver Dis 2002;22:27-37.
37. Rubbia-Brandt L, Audard V, Sartorelli P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15:460-6. (Pubitemid 38444550)
38. Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006;24:845-53.
39. Karoui M, Penna C, Amin-Hashem M, et al. Influence of chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006;243:1-7. (Pubitemid 43054046)
40. Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008;247:118-24.
41. Zorzi D, Laurent A, Pawlik TM, et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007;94:274-86. (Pubitemid 46423843)
42. Rubbia-Brandt L, Mentha G, Terris B. Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases. J Am Coll Surg 2006;202(1):199-200. (Pubitemid 41831492)
43. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:2065-72. (Pubitemid 46622116)
44. DeLeve LD, McCuskey RS, Wang X, et al. Characterization of a reproducible model of hepatic veno-occlusive disease. Hepatology 1999;29:1779-91. (Pubitemid 29247052)
45. Tisman G, MacDonald D, Shindell N, et al. Oxaliplatin toxicity masquerading as recurrent colon cancer. J Clin Oncol 2004;15:460-6.
46. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology 2005;41:1313-21. (Pubitemid 40770284)
47. Fong Y, Bentrem DJ. CASH (chemotherapy-associated steatohepatitis) costs. Ann Surg 2006;243:8-9. (Pubitemid 43054047)
48. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005;200:845-53. (Pubitemid 40744790)
49. Brouquet A, Benoist S, Julie C, et al. Risk factors for chemotherapy-associated liver injuries: a multivariate analysis of a group of 146 patients with colorectal metastases. Surgery 2009;145:362-71.
50. Klinger M, Eipeldauer S, Hacker S, et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 2009;35:515-20.
51. Panaro F, Casnedi S, Zeca I, Bachellier P, Chenard MP, Pessaux P. Conséquences cliniques, biologiques et histologiques du cetuximab et du bevacizumab après hépatectomie pour métastases d'origine colorectale : étude cas-témoin. J Chir 2008;145:10S26.
52. Iguchi A, Kobayashi R, Yoshida M, et al. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation. Bone Marrow Transplant 2001;27:1173-80. (Pubitemid 32600290)
53. Deleve LD, Wang X, Tsai J, Kanel G, Strasberg S, Tokes ZA. Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition. Gastroenterology 2003;125:882-90. (Pubitemid 37070704)
54. Kooby DA, Stockman J, Ben-Porat L, et al. Influence of transfusions on perioperative and long-term outcome in patients following resection for colorectal metastases. Ann Surg 2003;237:860-70. (Pubitemid 38174522)
55. Angitapalli R, Litwin AM, Kumar PR, et al. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer. Oncology 2009;76:363-8.
56. Berhrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 1998;2:292-8. (Pubitemid 128409616)
57. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000;191:38-46. (Pubitemid 30439557)
58. D'Angelica M, Kornprat P, Gonen M, et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 2007;14:759-65. (Pubitemid 46175324)
59. Reddy SK, Morse MA, Hurwitz HI, et al. Addition of bevacizumab to irinotecan and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008;206:96-106. (Pubitemid 350267242)
60. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006;24:3939-45. (Pubitemid 46630742)
61. Fiorentini G, Del Conte A, De Simone M, et al. Complete response of colorectal liver metastases after intra-arterial chemotherapy. Tumori 2008;94:489-92.
62. Elias D, Youssef O, Sideris L, et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 2004;86:4-9. (Pubitemid 38490093)
63. Elias D, Goere D, Boige V, et al. Outcome of posthepatectomymissing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007;14:3188-94. (Pubitemid 47594272)
64. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224:748-56. (Pubitemid 34919808)
65. Bipat S, van Leeuwen MS, Comans EFI, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis: metaanalysis. Radiology 2005;237:123-31. (Pubitemid 41346155)
66. Kamel IR, Bluemke DA. MR imaging of liver tumors. Radiol Clin North Am 2003;41:51-65. (Pubitemid 36259126)
67. Scott DJ, Guthrie JA, Arnold P, et al. Dual phase helical CT versus portal venous phase CT for the detection of colorectal liver metastases: correlation with intra-operative sonography, surgical and pathological findings. Clin Radiol 2001;56:235-42.
68. Sica GT, Ji H, Ross PR. CT and MR imaging of hepatic metastases. AJR Am J Roentgenol 2000;174:691-8. (Pubitemid 30126248)
69. Rappeport ED, Loft A. Liver metastases from colorectal cancer: imaging with superparamagnetic iron oxide (SPIO)-enhanced MR imaging, computed tomography and positron emission tomography. Abdom Imaging 2007;32:624-34. (Pubitemid 47594251)
70. Angliviel B, Benoist S, Penna C, et al. Impact of chemotherapy on the accuracy of computed tomography scan for evaluation of colorectal liver metastases. Ann Surg Oncol 2009;16:1247-53.
71. Lubezky N, Metser U, Geva R, et al. The role and limitations of 18-fluoro-2-d-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 2007;11:472-8.
72. Beal IK, Anthony S, Papadopoulou A, et al. Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy. Br J Radiol 2006;79:473-8. (Pubitemid 43933443)
73. Goere D, Farges O, Leporrier J, et al. Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction. J Gastrointest Surg 2006;10:365-70. (Pubitemid 43303830)
74. LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, et al. Angiogenesis-independant endothelial protection of liver: role of VEGFR-1. Science 2003;299:890-3. (Pubitemid 36182447)
75. Hicklin DJ, Ellis LM. Role of vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27. (Pubitemid 46202320)
76. Aussilhou B, Dokmak S, Faivre S, Paradis V, Vilgrain V, Belghiti J. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 2009;16: 1553-9.
77. Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 2008;15: 2765-72.